Efficacy and safety of perampanel monotherapy in Chinese children with newly diagnosed focal epilepsy: a single-center prospective study.

ABSTRACT:

Background

Focal epilepsy is the most common type of epilepsy in children. Antiseizure medications (ASMs) are the main treatment for focal epilepsy at present. Perampanel (PER), as a competitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid of glutamate receptor, have been used for treatment for focal epilepsy in children in western countries. The purpose of our research was to evaluate the efficacy and safety of PER monotherapy in children (aged 2-12 years) with newly diagnosed focal epilepsy in China.

Methods

In this single-center prospective study, Chinese children with newly diagnosed epilepsy (range 2 to 12 years) were enrolled. After 4 to 8 weeks titration period, patients received PER monotherapy in a 24-week treatment phase. The primary endpoint

SUBMITTER: Hong Y 

PROVIDER: S-EPMC12597179 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature